On March 30, 2026, Protara Therapeutics, Inc. announced significant progress in its ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002, a treatment for patients with carcinoma in situ or CIS (± Ta/T1) non-muscle invasive bladder cancer (NMIBC). The company reported a six-month complete response (CR) rate of 68.0% among the 25 BCG-Unresponsive patients enrolled in the trial. This result is consistent with the previously announced 68.2% CR rate reported on February 24, 2026, and notably exceeds the historical average of 41.9% for similar patient populations. The positive outcomes from this trial are expected to enhance Protara's position in the bladder cancer treatment market and may lead to further investment and interest from stakeholders. Additionally, the company confirmed that it has met the conditions set forth in its common stock purchase warrants issued in April 2024, allowing for the exercise of these warrants at an exercise price of $5.25 per share until June 29, 2026. This development is likely to bolster investor confidence and provide additional liquidity for the company as it continues to advance its clinical programs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.